Innovate UK has presented Oxford BioMedica (OXB), a gene and cell therapy company, with a £2 million funding package to aid its digital framework enterprise.
The initiative will assist with the development and production of next-generation medicines, and streamline processes as much as possible.
Oxford BioMedica is expected to invest a grand sum of £4 million with the end goal of increasing capacity, cutting manufacturing costs and the amount of waste generated.
The money will go towards improving digital and robotics facilities which will further improve analytical processes, supply efficiencies and assist with cost minimisation.
Chief executive of Oxford BioMedica, John Dawson, said: "With demand for advanced therapy medicinal products expected to grow at unprecedented levels, underlined by the interest received from our current and future potential partners at OXB, it is imperative that we continue to invest in our technology, capacity and innovation.
"This new initiative will provide us with digital and robotic enhancements to maintain our global leading position in the development and manufacture of lentiviral vector products. This is important for our own R&D pipeline as well as for our blue-chip partners as we continue to support the delivery of life-altering gene therapies to patients around the world."
The investment comes after Oxford BioMedica announced in September this year that it would be expanding its manufacturing facilities, which is anticipated to create 100 jobs in the following two years.